9344. Antinuclear antibodies (ANA, method IFT)

Antinuclear antibodies are a group of antibodies produced by the human immune system against substances in the cell nucleus (hence the name antinuclear or antinuclear). Determining ANA with this method allows for the assessment of the full spectrum of antinuclear antibodies and is used for screening for symptoms such as fatigue, fever, headache, joint damage, jaundice, and itchy skin.

It is used to diagnose systemic lupus erythematosus (SLE), CTD, Sjögren's syndrome, autoimmune hepatitis, primary biliary cirrhosis, polyneuropathy, and other diseases.

It is advisable to conduct a combination of tests to determine rheumatoid factor and C-reactive protein levels, supplemented by the determination of specific antibodies to antigens depending on the clinical picture.

Antinuclear antibodies (ANA) are a group of autoantibodies that react with various components of the nucleus. Determination of ANA antibodies in serum is a test for systemic connective tissue diseases.

The primary goal of this test is to rule out systemic lupus erythematosus (SLE), as ANA are detected in 95% of patients with this disease within 3 months of its onset.

A positive test result indicates the presence of one or a combination of ANA types. A negative test result in more than 95% of cases allows us to rule out systemic lupus erythematosus (SLE), drug-induced lupus erythematosus (DILE), scleroderma, CTD, systemic sclerosis, dermatomyositis, and polymyositis.

Screening diagnostics of autoimmune diseases.

• Venous blood

In order to exclude factors that may affect the test results, we recommend to follow the preparation rules: